Harrow Q2 Earnings Call Highlights

5 days ago 5

MarketBeat

Tue, August 11, 2026 astatine 10:05 AM CDT 7 min read

Key Points

Interested successful Harrow, Inc.? Here are 5 stocks we similar better.
Q2 gross roseate 11% twelvemonth implicit twelvemonth to $70.7 million, driven by stronger request for VEVYE, IHEEZO and specialty products. Harrow reiterated its full-year gross guidance of $350 million–$365 cardinal and adjusted EBITDA guidance of $80 million–$100 million.
Management expects second-half maturation from improved VEVYE pricing and expanded commercialized coverage, IHEEZO's 25% nett terms increase, BYOOVIZ and the relaunch of VERKAZIA. Gross margins are expected to retrieve toward the high-70% range.
Harrow plans to get planetary rights to TYRVAYA for $30 cardinal successful cash, with much than $30 cardinal of gross expected successful 2027 if the woody closes. The institution besides precocious pipeline programs G-MELT and YOCHIL, targeting aboriginal FDA submissions.

Harrow (NASDAQ:HROW) reported second-quarter gross of $70.7 million, up 11% from a twelvemonth earlier and astir 60% sequentially, arsenic the ophthalmic pharmaceutical institution said it entered the 2nd fractional of 2026 with stronger request crossed respective products, improved pricing and expanded commercialized infrastructure.

First-half gross totaled astir $115 million, which Chief Executive Officer Mark L. Baum said was beneath the company's expectations entering the year, chiefly due to the fact that of the nett gross interaction from VEVYE. Harrow nevertheless reiterated its full-year guidance for gross of $350 cardinal to $365 cardinal and adjusted EBITDA of $80 cardinal to $100 million.

→ SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat

The outlook implies second-half gross of astir $235 cardinal to $250 million. President and Chief Financial Officer Andrew Boll said the institution expects sequential gross maturation successful some the 3rd and 4th quarters, with the larger summation expected successful the 4th quarter.

Second-Quarter Results and Margin Outlook

VEVYE generated quarterly gross of $29.4 million, up astir 58% twelvemonth implicit year. Baum said prescriptions accrued 21% sequentially, portion the prescriber basal expanded 15%. The merchandise ended June with a 14.6% stock of the branded adust oculus market, according to IQVIA information cited by Chief Commercial Officer Patrick Sullivan.

→ Take-Two's Q1 Results Leave GTA 6 Bulls Stuck successful the Fog of War

Harrow changed VEVYE concern rules astatine the extremity of April, reducing co-pay paper utilization and improving the product's mean selling price, according to management. Boll said the institution expects further pricing betterment successful the 2nd fractional arsenic the updated rules use for a afloat period, patients conscionable yearly deductibles and expanded commercialized sum takes effect.

Read Entire Article